Pluri Inc. (PLUR) Form 10-K — Sep 10, 2026
Pluri Inc.'s fiscal 2026 10-K carries a going-concern qualification: the auditor flagged substantial doubt about the company's ability to continue as a going concern, and management estimates cash balances of $8,851,000 at June 30, 2026 cover less than three months of operating obligations, with additional capital required imminently. The company is out of compliance with Nasdaq's $35 million market-value-of-listed-securities requirement (Rule 5550(b)(2)) and also fails the alternative equity/net-income standards; it has until January 4, 2027 to regain compliance or face potential delisting.
Key figures
- Total Debt
- €20 million EIB loan principal plus approximately €4.1 million accrued interest as of June 30, 2026
- Cash Position
- 8851000
- Shares Outstanding
- 12344736
- Employees
- 92 full-time and 21 part-time as of June 30, 2026
- Issued Patents
- 149
- Bia Revenue Share
- 20% of future sales of PLX cocaine anti-addiction product assigned to BIRAD
- Eib Interest Rate
- 4% per annum
- Eib Maturity Date
- 2026-06-01 (unpaid; EIB reserving rights)
- Operating Runway
- less than three months per management estimate
- Proto Grant Value
- €7.5 million Horizon Europe grant; $449,000 cash received by Pluri through June 30, 2026
- Eib Loan Principal
- €20 million (sole disbursed tranche, received June 2021)
- Kokomodo Ownership
- approximately 79%
- Eib Accrued Interest
- approximately €4.1 million as of June 30, 2026
- Ever After Ownership
- approximately 58% after Fishway Acquisition (down from ~69%)
- Eib Accrued Royalties
- $9 thousand as of June 30, 2026
- Non Affiliate Market Value
- 15189234
- Nasdaq Compliance Deadline
- 2027-01-04
- Nasdaq Mvls Requirement Usd
- 35000000
- Pending Patent Applications
- approximately 57 (5 allowed but not yet granted)
Price after filing
Close on the filing date to close N calendar days later (from $1.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.